Antisoma: Novartis Will Include Non-Squamous NSCLC Patients In Phase III ASA404 Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision to include both squamous and non-squamous cancer types doubles the study population and indicates ASA404 may compete with Avastin.